Last reviewed · How we verify
Nebulized 3% sodium chloride solution
Nebulized hypertonic saline draws fluid into the airways through osmotic gradient, hydrating secretions and promoting mucus clearance.
Nebulized hypertonic saline draws fluid into the airways through osmotic gradient, hydrating secretions and promoting mucus clearance. Used for Cystic fibrosis, Bronchiectasis, Chronic bronchitis with mucus impaction.
At a glance
| Generic name | Nebulized 3% sodium chloride solution |
|---|---|
| Sponsor | NYU Langone Health |
| Drug class | Mucolytic/secretion mobilizer |
| Modality | Small molecule |
| Therapeutic area | Pulmonology/Respiratory |
| Phase | FDA-approved |
Mechanism of action
When inhaled as an aerosol, the 3% sodium chloride solution creates an osmotic gradient across the airway epithelium, drawing water into the mucus layer and increasing its hydration. This reduces mucus viscosity and improves mucociliary clearance, facilitating expectoration of secretions and improving airway patency. The mechanism is purely physical/osmotic rather than pharmacological.
Approved indications
- Cystic fibrosis
- Bronchiectasis
- Chronic bronchitis with mucus impaction
- Atelectasis due to mucus plugging
Common side effects
- Cough
- Bronchospasm
- Throat irritation
- Wheezing
Key clinical trials
- The Effect of NAC on Lung Function and CT Mucus Score (PHASE4)
- Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia (PHASE2, PHASE3)
- Efficacy Of Combined Nebulized Hypertonic Saline and Chest Percussion Therapy in Acute Viral Bronchiolitis (PHASE4)
- Predicting Post Extubation Stridor After Maxillomandibular Fixation (NA)
- Effect of Ipratropium Bromide on EILO (PHASE2)
- Oral Melatonin Versus Nebulized Dexmedetomidine on Emergence Agitation in Children Undergoing Adenotonsillectomy (NA)
- TranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage: Pilot Study (EARLY_PHASE1)
- Efficacy of Nebulized Dexmedetomidine on Blunting Hemodynamic Changes During Intubation and Pneumoperitoneum in Morbid Obese Patients During Laparoscopic Bariatric Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nebulized 3% sodium chloride solution CI brief — competitive landscape report
- Nebulized 3% sodium chloride solution updates RSS · CI watch RSS
- NYU Langone Health portfolio CI